Home › Conditions › Tumour Lysis Syndrome (TLS)
Oncology
Tumour Lysis Syndrome (TLS)
Tumour lysis syndrome (TLS) results from rapid malignant cell death releasing intracellular contents. Adult Cairo-Bishop lab TLS: ≥2 different metabolic abnormalities within 3 days before to 7 days after treatment. Count urate ≥476 μmol/L, K+ ≥6 mmol/L, phosphate ≥1.45 mmol/L or Ca²⁺ ≤1.75 mmol/L; the same parameter can instead qualify by a ≥25% rise (urate/K/phosphate) or ≥25% fall (calcium). Clinical TLS adds creatinine ≥1.5× ULN, arrhythmia or seizure. High-risk tumours include Burkitt's lymphoma, ALL with high WBC. Venetoclax-treated CLL has low–high TLS risk, depending on tumour burden and patient factors.
BSH Tumour Lysis Syndrome Guideline
The pathway
Risk stratify before chemotherapy
- High risk: Burkitt/lymphoblastic lymphoma if advanced stage, or early stage with LDH ≥2× ULN or bulky disease; ALL with WBC ≥100×10⁹/L and/or bulky disease; AML with WBC ≥100×10⁹/L
- Other high-grade lymphoma: early stage + normal LDH/non-bulky = low; early stage + raised LDH/bulk, or advanced stage + normal LDH/non-bulky = intermediate; advanced stage + LDH ≥2× ULN or bulk = high
- Intermediate: AML/ALL below 100×10⁹/L without the high-risk modifiers; early Burkitt/lymphoblastic lymphoma with LDH <2× ULN and no bulk
- Generally low: low-grade lymphomas, CLL on BTK inhibitors/alkylating therapy, conventional-treatment myeloma and most solid tumours. Renal dysfunction, spontaneous TLS and treatment-specific risks can upgrade the plan
- Venetoclax in CLL: low–high risk. High tumour burden: any node ≥10cm, or node ≥5cm plus ALC ≥25×10⁹/L; renal impairment (CrCl <80ml/min) increases risk. Use the CLL dose-ramp-up, prophylaxis and blood-monitoring schedule
IV hydration
- Adult prevention: 2–3 L/day total oral/IV fluid, starting the day before treatment; consider IV 0.9% NaCl if high risk or unable to drink enough
- Established TLS: initially 3 L/m²/day IV, aiming for urine output 100 mL/m²/hr; adjust to renal function, clinical status and fluid balance
- Avoid potassium and phosphate in IV fluids
- Do NOT alkalinise with bicarbonate — worsens calcium phosphate precipitation
Allopurinol for low/intermediate risk
- Allopurinol 300mg OD PO starting 24–48h before chemotherapy
- Reduces de novo uric acid synthesis but does not degrade pre-existing uric acid
- Reduce dose in renal impairment (e.g. 100mg OD); severe impairment may need <100mg/day or 100mg at longer intervals — confirm with haematology/pharmacy.
- Not adequate alone for high-risk patients
Rasburicase for high risk or established TLS
- Rasburicase 0.2mg/kg IV — rapidly degrades uric acid to water-soluble allantoin
- CONTRAINDICATED in G6PD deficiency → causes haemolytic anaemia — check G6PD status before prescribing
- Very unwell with delayed G6PD result: responsible consultant decides urgent treatment after individual risk–benefit review; never give in known G6PD deficiency.
- Stop allopurinol when rasburicase starts; it may restart 24 h after the last dose.
- Can repeat daily for up to 5–7 days
- Uric acid samples must be kept on ice (rasburicase degrades uric acid ex vivo at room temperature)
Manage electrolyte abnormalities
- Hyperkalaemia: urgent ECG; if hyperkalaemic ECG changes, calcium gluconate 10% 30ml IV over 10 min for membrane stabilisation, then insulin-glucose (10 units Actrapid in 25g glucose).
- BM at 0, 30, 60, 90 and 120 minutes, then hourly to 6 hours; if pre-treatment BM <7, follow with 10% glucose 50ml/hr for 5 hours
- Add a binder — sodium zirconium cyclosilicate or patiromer. Calcium resonium was dropped from the UKKA 2023 emergency algorithm
- Hyperphosphataemia: phosphate binders (sevelamer or aluminium hydroxide), dietary restriction
- Hypocalcaemia: treat only if symptomatic (tetany, seizures) — correcting phosphate first prevents calcium phosphate precipitation
Intensive monitoring
- Bloods every 6–8 hours: U&E, uric acid, phosphate, calcium, LDH, creatinine
- Hourly urine output — catheterise if output uncertain
- Continuous ECG monitoring (hyperkalaemia → peaked T waves, widened QRS, sine wave)
- Daily weight and fluid balance
Haemodialysis indications
- Refractory hyperkalaemia (e.g. K+ ≥6.5 mmol/L): urgent nephrology/ICU; do not wait for ECG changes
- Oliguria/anuria with fluid overload, refractory acidosis or uraemic complications: urgent RRT assessment
- With AKI/low urine output, refractory hyperuricaemia, hyperphosphataemia or symptomatic hypocalcaemia: discuss RRT early
- No fixed creatinine or isolated urate cutoff; assess the whole clinical condition and ongoing lysis
- Liaise with nephrology and haematology early — do not wait for deterioration
Drugs
| Drug | Dose | Route | Notes |
|---|---|---|---|
| Allopurinol | 300mg OD | PO | Low/intermediate risk prophylaxis. Start 24–48h before chemotherapy. Renal impairment: e.g. 100mg OD; severe impairment may need <100mg/day or 100mg at longer intervals. Confirm with haematology/pharmacy. |
| Rasburicase | 0.2mg/kg OD | IV | High risk or established TLS. CONTRAINDICATED in G6PD deficiency — haemolytic anaemia risk. Keep uric acid sample on ice. Very unwell with delayed G6PD result: responsible consultant decides urgent treatment after individual risk–benefit review; never give in known G6PD deficiency. Stop allopurinol when rasburicase starts; it may restart 24 h after the last dose. |
| Calcium gluconate 10% | 30ml over 10 min | IV | Membrane stabilisation in hyperkalaemia with ECG changes. Does not lower serum K+. |
| Insulin (Actrapid) + Dextrose 50% | 10 units + 50ml | IV | Shifts K+ intracellularly in 20–30 minutes. BM at 0, 30, 60, 90 and 120 minutes, then hourly to 6 hours. If pre-treatment BM <7.0, follow with 10% glucose 50ml/hr for 5 hours (UKKA 2026). |
| Sodium zirconium cyclosilicate | 10g TDS (up to 72h) | Oral | Removes K+ from body. Replaced calcium resonium in the UKKA 2023 emergency algorithm. Onset ~1h. Use alongside rapid-acting agents, never instead of them. |
When to escalate
- Refractory/life-threatening hyperkalaemia (e.g. K+ ≥6.5 mmol/L) — urgent nephrology/ICU for RRT; do not wait for ECG changes
- Persistent hyperuricaemia despite rasburicase, with AKI/low urine output — early nephrology/ICU review for RRT
- Oliguria — catheterise, review renal function and fluid balance, and urgently involve nephrology; do not force fluids into anuria or overload
- Symptomatic hypocalcaemia (tetany, seizures) — IV calcium gluconate; correct hyperphosphataemia concurrently
- G6PD-deficient patient developing TLS — rasburicase contraindicated; allopurinol + aggressive hydration + early haemodialysis
- Clinical TLS (AKI, arrhythmia, or seizure) — HDU/ITU, continuous cardiac monitoring, emergency nephrology
Reference: BSH Updated guidelines for the diagnosis and management of tumour lysis syndrome in adults and children (2025)
Practise and explore
Practise a case or explore differentials here on the website. The optional browser app adds personal learning tools and saved progress.